APA (7th ed.) Citation

NW, K., JYH, L., CY, L., TC, L., KSK, C., W, D., . . . DLW, K. (2025). Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition. Clinical and translational medicine, 15(11), e70535. https://doi.org/10.1002/ctm2.70535

Chicago Style (17th ed.) Citation

NW, Kam, Lau JYH, Lau CY, Lam TC, Chan KSK, Dai W, Fun VLH, Chiang CL, and Kwong DLW. "Pre-existing CD95-based Temra Immunity in Patients with Recurrent/metastatic Nasopharyngeal Carcinoma Predicts Response and Hyperprogression to Dual PD-L1 and TGFβ Inhibition." Clinical and Translational Medicine 15, no. 11 (2025): e70535. https://doi.org/10.1002/ctm2.70535.

MLA (9th ed.) Citation

NW, Kam, et al. "Pre-existing CD95-based Temra Immunity in Patients with Recurrent/metastatic Nasopharyngeal Carcinoma Predicts Response and Hyperprogression to Dual PD-L1 and TGFβ Inhibition." Clinical and Translational Medicine, vol. 15, no. 11, 2025, p. e70535, https://doi.org/10.1002/ctm2.70535.